ALS drug trial halted: safety data sought from 54 patients

NCT ID NCT06215755

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called VRG50635 in 54 people with ALS (Lou Gehrig's disease). The main goal was to check if the drug is safe and how the body processes it. The trial was stopped early, but researchers were looking for side effects and changes in disease progression.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis amyotrophic lateral sclerosis type 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Helsinki University Hospital

    Helsinki, Uusimaa, FI-00029, Finland

  • Stan Cassidy Centre for Rehabilitation (Horizon NB)

    Montreal, Quebec, H3A 2B4, Canada

  • The Neuro - Montréal Neurological Institute-Hospital

    Montreal, Quebec, H3A 2B4, Canada

  • Turku University Hospital

    Turku, Western Finland, FI-20520, Finland

  • UZ Leuven

    Leuven, Flemish Brabant, Belgium

  • University Medical Center Utrecht

    Utrecht, 3584 CX, Netherlands

  • University of Eastern Finland, Brain Research Unit

    Kuopio, Eastern Finland, FI-70210, Finland